Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Equity Income (2022 - 2023)

Historic Equity Income for Zentalis Pharmaceuticals (ZNTL) over the last 2 years, with Q2 2023 value amounting to -$13.7 million.

  • Zentalis Pharmaceuticals' Equity Income fell 15672.54% to -$13.7 million in Q2 2023 from the same period last year, while for Mar 2024 it was -$13.7 million, marking a year-over-year increase of 1862.72%. This contributed to the annual value of -$16.0 million for FY2023, which is 164.6% up from last year.
  • Zentalis Pharmaceuticals' Equity Income amounted to -$13.7 million in Q2 2023, which was down 15672.54% from -$2.3 million recorded in Q1 2023.
  • In the past 5 years, Zentalis Pharmaceuticals' Equity Income ranged from a high of -$1.8 million in Q1 2022 and a low of -$13.7 million during Q2 2023